B-cell lymphoma

Disease ID:1048
Name:B-cell lymphoma
Associated with:1 target
3 immuno-relevant ligands
Database Links
Disease Ontology: DOID:707

Targets

CIITA

Ligands

Key to terms and symbols Click ligand name to view ligand summary Click column headers to sort
Ligand References Clinical and Disease comments
spebrutinib
Immuno Disease Comments: Phase 1 clinical candidate for B cell malignancies (see NCT01766583).
Clinical Use: Spebrutinib has been granted orphan drug designation by the EMA (using the chemical name n-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide benzenesulfonic acid salt) for the treatment of B-cell chronic lymphocytic leukemia (CLL). Spebrutinib (as research code CC-292) has been compared with placebo as a co-therapy with for active rheumatoid arthritis, in completed clinical trial NCT01975610. In addition it is in various Phase I trials for B-cell lymphomas. Click here to view these trials at ClinicalTrials.gov. | View clinical data
fenebrutinib
Immuno Disease Comments: Phase 2 clinical candidate for B cell lymphoma (see NCT01991184).
Clinical Use: GDC-0853 has reached Phase 2 clinical trial in patients with rheumatoid arthritis (RA: see NCT02833350), and Phase 1 in patients with resistant B-cell lymphoma or chronic lymphocytic leukemia (CLL). | View clinical data
otlertuzumab 1
Immuno Disease Comments: Phase 1b clinical candidate for indolent B-cell small lymphocytic lymphoma.
Clinical Use: Preliminary evidence of clinical efficacy in a small number of patients with highly refractory, heavily pretreated B-cell non-Hodgkin lymphoma has been reported [2]- see NCT00614042. A Phase 1b study of TRU-016 plus other biological or small molecule chemotherapeutic drugs (NCT01644253) is under way (May 2018). | View clinical data
Bioactivity Comments: Rafiq et al. (2013) [3] show a dose-respnse curve of TRU-016 binding to CD37 on Daudi cells (with the x axis labeled as 'ng/well' rather than as a defined molarity), but do not present a calculated affinity constant. | View biological activity

References

Show »

1. Gopal AK, Tarantolo SR, Bellam N, Green DJ, Griffin M, Feldman T, Mato AR, Eisenfeld AJ, Stromatt SC, Goy A. (2014) Phase 1b study of otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIRâ„¢ therapeutic protein, in combination with rituximab and bendamustine in relapsed indolent lymphoma patients. Invest New Drugs, 32 (6): 1213-25. [PMID:24927856]

2. Pagel JM, Spurgeon SE, Byrd JC, Awan FT, Flinn IW, Lanasa MC, Eisenfeld AJ, Stromatt SC, Gopal AK. (2015) Otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR(â„¢) therapeutic protein, for relapsed or refractory NHL patients. Br. J. Haematol., 168 (1): 38-45. [PMID:25146490]

3. Rafiq S, Siadak A, Butchar JP, Cheney C, Lozanski G, Jacob NK, Lapalombella R, McGourty J, Moledor M, Lowe R et al.. (2013) Glycovariant anti-CD37 monospecific protein therapeutic exhibits enhanced effector cell-mediated cytotoxicity against chronic and acute B cell malignancies. MAbs, 5 (5): 723-35. [PMID:23883821]